Ordinary income for the interim results for the fiscal year ending March 2027 was -¥315 million, while the full-year earnings forecast announced the same day is expected to leave ordinary income unchanged at ¥20 million.
ADRバイオメディカルホールディングス announced its interim results on 13 November. Ordinary loss was ¥315 million.
In its full-year earnings forecast announced the same day, the company left unchanged its previous forecast for ordinary income of ¥20 million.
Depending on future disclosures, additional information may be released regarding the interim loss and the feasibility of the full-year outlook.